Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RGNX)

REGENXBIO to Participate in Upcoming Investor Conference

PR Newswire 10 days ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

PR Newswire November 6, 2025

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

PR Newswire October 30, 2025

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

PR Newswire October 29, 2025

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire October 15, 2025

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

PR Newswire October 9, 2025

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

PR Newswire October 6, 2025

REGENXBIO Announces Presentation at the World Muscle Society

PR Newswire September 29, 2025

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

PR Newswire September 5, 2025
View More News ››

Opinion & Analysis (NDAQ:RGNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RGNX)

REGENXBIO Inc. (NASDAQ:RGNX) Poised for Significant Value Ge

http://beyondspx.com/2024/07/31/regenxbio-inc-nasdaqrgnx-poised-for-significant-value-generation-in-2024-and-beyond/
MikeTester - August 2, 2024

RegenxBio Inc: A Compelling Investment Opportunity!

Excited to share an article on RegenxBio, Inc (NASDAQ: RGNX), a leader in gene therapy , whose NAV technology platform is behind...
AviseAnalytics - August 10, 2021

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021
View more Bullboard ››

LaFleur Minerals Inc.

LaFleur Minerals Inc.

LaFleur Minerals Inc. explores for lithium and gold deposits in Canada. The company holds interest in the Swanson Gold ...
View More »